EMEA-002952-PIP01-21 - paediatric investigation plan

Bamlanivimab

Key facts

• Active Substance:
  Bamlanivimab
• Therapeutic area:
  Infectious diseases
• Decision number:
  P/0221/2021
• PIP number:
  EMEA-002952-PIP01-21
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of Coronavirus disease 2019 (COVID-19)
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Eli Lilly and Company Ltd; E-mail: [e-mail] ; Phone: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  09/06/2021

Decision

P/0221/2021: EMA decision of 9 June 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for bamlanivimab (EMEA-002952-PIP01-21)

AdoptedReference Number: EMA/245846/2021